Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 1.0 | 4.0 |
Min SIP Amount | ₹200 | ₹100 |
Expense Ratio | 2.45 | 1.89 |
NAV | ₹28.59 | ₹39.03 |
Fund Started | 08 Feb 2019 | 25 Jun 2018 |
Fund Size | ₹84.19 Cr | ₹5507.52 Cr |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 16.43% | 22.01% |
3 Year | 20.93% | 29.41% |
5 Year | 16.92% | 24.24% |
1 Year
3 Year
5 Year
Equity | 96.62% | 96.99% |
Cash | 3.38% | 3.01% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.73% |
Cipla Ltd. | 5.43% |
Torrent Pharmaceuticals Ltd. | 4.95% |
Divi's Laboratories Ltd. | 4.84% |
Aurobindo Pharma Ltd. | 4.27% |
Piramal Pharma Ltd. | 4.22% |
Neuland Laboratories Ltd. | 4.11% |
Fortis Healthcare Ltd. | 4.00% |
Alkem Laboratories Ltd. | 3.76% |
Artemis Medicare Services Ltd. | 3.61% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.66% |
Dr. Reddy's Laboratories Ltd. | 9.66% |
Divi's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 7.85% |
Aurobindo Pharma Ltd. | 6.34% |
Alkem Laboratories Ltd. | 4.12% |
Zydus Lifesciences Ltd. | 4.01% |
Lupin Ltd. | 3.98% |
Gland Pharma Ltd. | 3.95% |
Syngene International Ltd. | 2.46% |
Name | Karan Doshi | Dharmesh Kakkad |
Start Date | 31 Jul 2023 | 23 Feb 2021 |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 08 Feb 2019 | 25 Jun 2018 |
Description
Launch Date